cabozantinib
exelixis
['lcsm,(-blcsm)', '8524', 'atlantis', 'lurbinectedin']
#asco22 abs#8524 in #lcsm poster session! will present #post-hoc #analysis from #atlantis trial of #lurbinectedin in 2nd line, with single agent lurbinectedin showing maintained cr in those who achieved, pr to cr (12%), sd to pr/cr (16%) #adascovisabs 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own